Pathogenicity of Campylobacter pylori in the upper gastrointestinal tract--implications for modern therapy.
Monash University Department of Medicine.
J R
JR
Lambert
A J
AJ
McLean
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D002167:Campylobacter / Q000302:isolation & purification / Q000472:pathogenicity*; D002169:Campylobacter Infections / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D002908:Chronic Disease; D004381:Duodenal Ulcer / Q000188:drug therapy / Q000209:etiology*; D005756:Gastritis / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D009942:Organometallic Compounds / Q000627:therapeutic use; D011706:Pyloric Antrum / Q000382:microbiology; D012008:Recurrence; D012307:Risk Factors
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D009942:Organometallic Compounds; C002791:bismuth tripotassium dicitrate